All In Biotech

NDA 009768 · Advanz Pharma

Plaquenil

Hydroxychloroquine Sulfate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1955

Apr 18, 1955

Approved uses

1

Original approval plus efficacy supplements

Registered trials

544

162 Phase 3, 62 recruiting

FAERS reports

91,641

68,992 serious, 6,486 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 9, 2026.

PLAQUENIL is an antimalarial and antirheumatic indicated for the: • Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax in adult and pediatric patients. (1.1) • Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. (1.1) • Treatment of rheumatoid arthritis in adults. (1.2) • Treatment of systemic lupus erythematosus in adults. (1.3) • Treatment of chronic discoid lupus erythematosus in adults. (1.4) Limitations of Use (1.1): PLAQUENIL is not recommended for the: • Treatment of complicated malaria. • Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. • Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Prophylaxis of malaria in geographic areas where chloroquine resistance occurs. • Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. 1.1 Malaria PLAQUENIL is indicated in adult and pediatric patients for the: • Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale. • Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: PLAQUENIL is not recommended for: • Treatment of complicated malaria. • Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species [see Microbiology (12.4) ]. • Treatment of malaria acquired in geographic areas where chloroquine...

Mechanism: Malaria Hydroxychloroquine is a 4-aminoquinoline antimalarial [see Microbiology (12.4) ] and antirheumatic agent. Rheumatoid Arthritis, Systemic Lupus Erythematosus and Chronic Discoid Lupus Erythematosus The mechanisms underlying the anti-inflammatory and immunomodulatory effects of PLAQUENIL in the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus and systemic lupus erythematosus are not fully known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 18, 1955 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • PLAQUENIL · HYDROXYCHLOROQUINE SULFATE 200MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydroxychloroquine" as an intervention, any sponsor and status, largest first.

All 544 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective29,383
  • rheumatoid arthritis20,611
  • pain16,841
  • fatigue14,367
  • arthralgia14,050
  • drug intolerance12,522
  • joint swelling12,435
  • off label use11,521
  • rash10,890
  • abdominal discomfort9,834
  • contraindicated product administered9,728
  • alopecia9,672

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004639
2005603
2006927
20071,419
20081,525
20091,621
20101,439
20111,640
20122,381
20132,084
20142,448
20154,032
20164,898
20175,675
20186,669
20198,373
202012,455
20218,013
20226,960
20234,564
20245,329
20255,007
20262,940

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Plaquenil (Hydroxychloroquine Sulfate)

2024 spending

$5.6M

Beneficiaries

1,290

4,964 claims

Per beneficiary

$4,329

$11.60 per unit

View as table
YearSpending
2020$6,019,761
2021$6,143,405
2022$5,842,371
2023$5,999,787
2024$5,584,908

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 897 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.